PPPedro Nuno Palma

Pedro Nuno Palma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Nuno Palma has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

    by Maria‐João Bonifácio, Filipa Sousa, Cátia Aires, Ana I. Loureiro, Carlos Fernandes‐Lopes, Nuno M. Pires, Pedro Nuno Palma, Paul Moser, Patrício Soares‐Da‐Silva

    Background and Purpose: In 2016, one person died and four others had mild‐to‐severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10‐2474.Experimental Approach: Pharmacodynamic and pharmacokinetic studies were performed with BIA 10‐2474, PF‐04457845 and JNJ‐42165279 using mice, rats and human FAAH expressed in COS cells. Selectivity was evaluated by activity‐based protein profiling (APBB) in rats. BIA 10‐2474 effect in stroke‐prone spontaneously hypertensive rats (SHRSP) was investigated.Key Results: BIA 10‐2474 was 10‐fold less potent than PF‐04457845 in inhibiting human FAAH in situ but inhibited mouse brain and liver FAAH with ED50 values of 13.5 and 6.2 μg·kg−1, respectively. Plasma and brain BIA 10‐2474 levels were consistent with in situ potency and neither BIA 10‐2474 nor its metabolites accumulated following repeat administration. FAAH and α/β‐hydrolase domain containing 6 were the primary targets of BIA 10‐2474 and, at higher exposure levels, ABHD11, PNPLA6, PLA2G15, PLA2G6 and androgen‐induced protein 1. At 100 mg·kg−1 for 28 days, the level of several lipid species containing arachidonic acid increased. Daily treatment of SHRSP with BIA 10‐2474 did not affect mortality rate or increased the incidence of haemorrhage or oedema in surviving animals.Conclusions and Implications: BIA 10‐2474 potently inhibits FAAH in vivo, similarly to PF‐04457845 and interacts with a number of lipid processing enzymes, some previously identified in human cells as off‐targets particularly at high levels of exposure. These interactions occurred at doses used in toxicology studies, but the implication of these off‐targets in the clinical trial accident remains unclear.


  • Open Access

    Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

    by László E. Kiss, Alexandre Beliaev, Humberto S. Ferreira, Carla P. Rosa, Maria João Bonifácio, Ana I. Loureiro, Nuno M. Pires, P. Nuno Palma, Patrício Soares‐Da‐Silva

    Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain associated with various medical conditions. Herein we report the design and synthesis of a novel series of heterocyclic‐N‐carboxamide FAAH inhibitors that have a good alignment of potency, metabolic stability and selectivity for FAAH over monoacylglycerol lipase (MAGL) and carboxylesterases (CEs). Lead optimization efforts carried out with benzotriazolyl‐ and imidazolyl‐N‐carboxamide series led to the discovery of clinical candidate 8 l (3‐(1‐(cyclohexyl(methyl)carbamoyl)‐1H‐imidazol‐4‐yl)pyridine 1‐oxide; BIA 10‐2474) as a potent and long‐acting inhibitor of FAAH. However, during a Phase I clinical trial with compound 8 l, unexpected and unpredictable serious neurological adverse events occurred, affecting five healthy volunteers, including the death of one subject.


  • Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide

    by Simon Hebeisen, Nuno Pires, Ana I. Loureiro, Maria João Bonifácio, Nuno Palma, Andrew Whyment, David Spanswick, Patrício Soares-Da-Silva


  • Catechol‐O‐Methyl‐Transferase Inhibitors: Present Problems and Relevance of the New Ones

    by P. Nuno Palma, László E. Kiss, Patrício Soares‐Da‐Silva

    Levodopa, in association with a DOPA decarboxylase inhibitor (e.g., carbidopa or benserazide) has for many years been the undisputed gold standard drug for the symptomatic treatment of Parkinson’s disease (PD). However, given its rapid disposition and elimination in the periphery, it was hypothesized that significant enhancements in levodopa bioavailability and clinical efficacy could be achieved through co‐adjuvant therapy with a catechol‐O‐methyl‐transferase (COMT) inhibitor. Early attempts, dating back to the late 1950s, to discover COMT inhibitors were generally hampered by their lack of in vivo efficacy, target selectivity or by considerable toxicity. It was not until the late 1990s that entacapone and tolcapone, representatives of a new class of potent COMT inhibitors (nitrocatechol derivatives), made their way to clinical practice for the treatment of PD. Even though these drugs have since contributed to an increase in the usefulness of levodopa therapy, each of them presents known limitations, namely concerning their clinical efficacy and safety. The unmet medical need for more efficacious and safer COMT inhibitors has motivated intense research in this field over the last decade. Opicapone is the first, third‐generation COMT inhibitor among the nitrocatechol derivatives under clinical development, and demonstrates superior pharmacodynamic and safety profiles in humans, over previous drugs. In this chapter, we review the major advances in this field, summarize the relevant non‐clinical and clinical human pharmacology and discuss new insights into the mechanism of action of opicapone.


  • Open Access

    Opicapone: a short lived and very long acting novel catechol‐O‐methyltransferase inhibitor following multiple dose administration in healthy subjects

    by José Francisco Rocha, Luis Almeida, Amílcar Falcão, P. Nuno Palma, Ana I. Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C. Wright, Teresa Nunes, Patrício Soares‐Da‐Silva

    Aims: The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol‐O‐methyltransferase (S‐COMT) activity following repeated doses of opicapone.Methods: This randomized, placebo‐controlled, double‐blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30 mg for 8 days.Results: Opicapone was well tolerated. Its systemic exposure increased in an approximately dose‐proportional manner with an apparent terminal half‐life of 1.0 to 1.4 h. Sulphation was the main metabolic pathway. Opicapone metabolites recovered in urine accounted for less than 3% of the amount of opicapone administered suggesting that bile is likely the main route of excretion. Maximum S‐COMT inhibition (Emax) ranged from 69.9% to 98.0% following the last dose of opicapone. The opicapone‐induced S‐COMT inhibition showed a half‐life in excess of 100 h, which was dose‐independent and much longer than plasma drug exposure. Such a half‐life translates into a putative underlying rate constant that is comparable with the estimated dissociation rate constant of the COMT–opicapone complex.Conclusion: Despite its short elimination half‐life, opicapone markedly and sustainably inhibited erythrocyte S‐COMT activity making it suitable for a once daily regimen.


  • Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects

    by Luis Almeida, José Francisco Rocha, Amílcar Falcão, P. Nuno Palma, Ana I. Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C. Wright, Teresa Nunes, Patrício Soares-Da-Silva

    Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers.


  • Computation of the binding affinities of catechol‐O‐methyltransferase inhibitors: Multisubstate relative free energy calculations

    by P. Nuno Palma, Maria João Bonifácio, Ana Isabel Loureiro, Patrício Soares‐Da‐Silva

    Alchemical free energy simulations are amongst the most accurate techniques for the computation of the free energy changes associated with noncovalent protein–ligand interactions. A procedure is presented to estimate the relative binding free energies of several ligands to the same protein target where multiple, low‐energy configurational substates might coexist, as opposed to one unique structure. The contributions of all individual substates were estimated, explicitly, with the free energy perturbation method, and combined in a rigorous fashion to compute the overall relative binding free energies and dissociation constants. It is shown that, unless the most stable bound forms are knowna priori, inaccurate results may be obtained if the contributions of multiple substates are ignored. The method was applied to study the complex formed between human catechol‐O‐methyltransferase and BIA 9‐1067, a newly developed tight‐binding inhibitor that is currently under clinical evaluation for the therapy of Parkinson's disease. Our results reveal an exceptionally high‐binding affinity (Kdin subpicomolar range) and provide insightful clues on the interactions and mechanism of inhibition. The inhibitor is, itself, a slowly reacting substrate of the target enzyme and is released from the complex in the form ofO‐methylated product. By comparing the experimental catalytic rate (kcat) and the estimated dissociation rate (koff) constants of the enzyme‐inhibitor complex, one can conclude that the observed inhibition potency (Ki) is primarily dependent on the catalytic rate constant of the inhibitor'sO‐methylation, rather than the rate constant of dissociation of the complex.


  • Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase

    by László E. Kiss, Humberto S. Ferreira, Leonel Torrão, Maria João Bonifácio, P. Nuno Palma, Patrício Soares-Da-Silva, David A. Learmonth

    Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to l-Dopa therapy of Parkinson's disease.


  • Open Access

    Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's Disease

    by Maria João Bonifácio, P. Nuno Palma, Luís Almeida, Patrício Soares‐Da‐Silva

    Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent reduction in striatal dopamine levels leading to characteristic motor symptoms. The most effective treatment for this disease continues to be the dopamine replacement therapy with levodopa together with an inhibitor of aromatic amino acid decarboxylase (AADC). The efficacy of this therapy, however, decreases with time and most patients develop fluctuating responses and dyskinesias. The last decade showed that the use of catechol‐O‐methyltransferase inhibitors as adjuvants to the levodopa/AADC inhibitor therapy, significantly improves the clinical benefits of this therapy.The purpose of this article is to review the current knowledge on the enzyme catechol‐O‐methyltransferase (COMT) and the role of COMT inhibitors in PD as a new therapeutic approach to PD involving conversion of levodopa to dopamine at the target region in the brain and facilitation of the continuous action of this amine at the receptor sites. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on nebicapone, presently under clinical development, as well as entacapone and tolcapone, which are already approved as adjuncts in the therapy of PD. This article reviews human pharmacokinetic and pharmacodynamic properties of these drugs as well as their clinical efficacy and safety.


  • Modelling the Electron‐Transfer Complex Between Aldehyde Oxidoreductase and Flavodoxin

    by Ludwig Krippahl, P. Nuno Palma, Isabel Moura, José J. G. Moura